When first line treatment is indicated, depending on the local situation, chemoimmunotherapy and use of Bruton tyrosine kinase inhibitors (BTK) inhibitors4 remain reasonable options—for patients that cannot travel because of the risk of contracting COVID-19, oral therapy may be a better option. This evidence concerns the gene BTK and COVID-19.